|
Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours. |
|
|
Consulting or Advisory Role - Theolytics |
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
|
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Ethicon/Johnson & Johnson; GlaxoSmithKline; Roche/Genentech; Tesaro |
Consulting or Advisory Role - Aptitude Health; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Global Oncology One; Roche/Genentech |
Research Funding - Myrovlytis Trust |
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
|
|
Stock and Other Ownership Interests - Theolytics |
|
|
|
|
Stock and Other Ownership Interests - Theolytics |
Patents, Royalties, Other Intellectual Property - PsiOxus Therapeutics |
|
|
No Relationships to Disclose |